MDT - Medtronic plc

Could AI Boost Growth at Medtronic?

Medtronic (NYSE: MDT) has grown revenue over the years thanks to its solid portfolio of medical devices. Medtronic has taken action, streamlining parts of the business and acquiring assets that could drive future revenue. Medtronic is incorporating AI into its devices more and more.

Should Income Investors Buy This Soon-to-Be Dividend King?

Imagine spending a lifetime building your investment portfolio only to worry about whether you will outlive the balance in your investment accounts. If you are exclusively buying growth stocks with the intent of eventually selling them off for capital gains to sustain your lifestyle, running out of money could be a possibility. Consider medical device maker Medtronic (NYSE: MDT).

3 Reliable Dividend Growth Stocks to Buy Hand Over Fist in June

Adding these well-respected dividend payers to your portfolio could give you a stream of passive income that grows throughout your retirement years.

Here's Why You Should Retain Medtronic (MDT) Stock for Now

Investors continue to be optimistic about Medtronic (MDT) on the robust performances of the Neurosurgery and Cardiovascular portfolios.

2 Newly Minted AI Stocks to Buy Right Now

Nowhere is this trend more evident than in the recent parabolic growth of graphics, computing, and networking solutions company Nvidia (NASDAQ: NVDA). Thanks to its central role as a pillar of global AI architecture, Nvidia has seen its market cap swell to nearly $1 trillion in 2023.

2 Healthcare AI Stocks to Buy on the Dip

Artificial intelligence (AI) could change the way we treat and prevent illnesses, which makes it a highly valuable opportunity for companies. In fact, the global AI healthcare market is set to reach more than $100 billion later this decade, a Markets and Markets report shows. Two perfect examples are biotech Moderna (NASDAQ: MRNA) and medical device giant Medtronic (NYSE: MDT).

Is It Too Late to Buy Medtronic's Stock?

History has shown that purchasing stocks in resilient companies that can weather market highs and lows is an effective long-term investment strategy. Ireland-based Medtronic (NYSE: MDT), a major player in the medical device industry, is one such company. For years, the company steadily increased its revenue and earnings, keeping its business stable.

Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome (Revised)

Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.

Medtronic (NYSE:MDT) Is Increasing Its Dividend To $0.69

Medtronic plc's ( NYSE:MDT ) periodic dividend will be increasing on the 14th of July to $0.69, with investors...

Why Medtronic Stock Sank Today

There was plenty of action in the company's shares in the wake of its divisive fourth-quarter results.

Medtronic (MDT) to Expand Diabetes Care With New Buyout

Medtronic's (MDT) latest acquisition will increase its capacity to assist more individuals with diabetes worldwide within a single, seamless Medtronic support ecosystem.

Medtronic (MDT) Q4 2023 Earnings Call Transcript

Joining me are Geoff Martha, Medtronic chairman and chief executive officer; and Karen Parkhill, Medtronic chief financial officer. Geoff and Karen will provide comments on the results of our fourth quarter and fiscal year 2023, which ended on April 28, 2023, and our outlook for fiscal year '24.

Medtronic (MDT) Q4 Earnings Beat Estimates, Margins Down

Strong growth in the Cardiovascular, Medical Surgical, and Neuroscience portfolios, and in Diabetes markets drove Medtronic (MDT) Q4 revenues.

Why Medtronic Stock Is Sinking Today

Shares of the medical device maker Medtronic (NYSE: MDT) were down by 5% on heavy volume as of 10:53 a.m. ET Thursday. Although Medtronic topped Wall Street's consensus forecasts for the three-month period, investors appear to be reacting negatively to the company's financial guidance. Management blamed a stubbornly strong dollar and persistently high inflation for this softer-than-expected financial guidance.

Medtronic stock drops amid earnings beat, forecast missing expectations

Yahoo Finance Live discusses a drop in shares of Medtronic after the medical device maker issued a weaker than expected forecast.

Compared to Estimates, Medtronic (MDT) Q4 Earnings: A Look at Key Metrics

The headline numbers for Medtronic (MDT) give insight into how the company performed in the quarter ended April 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

• 
  Here's What Key Metrics Tell Us About Kohl's (KSS) Q1 Earnings

  Zacks
• 
  Lowe's (LOW) Reports Q1 Earnings: What Key Metrics Have to Say

  Zacks

Medtronic (MDT) Beats Q4 Earnings and Revenue Estimates

Medtronic (MDT) delivered earnings and revenue surprises of 0.64% and 3.59%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?

Medtronic's profit forecast hit by stronger dollar, inflation

(Reuters) -Medtronic Plc on Thursday forecast annual profit below Wall Street estimates, as a strong U.S. dollar and persistently high costs of raw goods weighed on the medical device maker's earnings, sending its shares down more than 4% in early trading. The company warned in February that rising raw material prices and high wages due to stubbornly high inflation would continue to impact its full-year profit. Medtronic forecast profit of $5 per share to $5.10 per share for the fiscal year 2024, below analysts' estimates of $5.20 per share, according to Refinitiv.

Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome

Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.

Medtronic Stock: Bull vs. Bear

Medtronic (NYSE: MDT) is on a roll. Its shares have soared close to 15% year to date, easily outperforming the S&P 500. But is Medtronic a stock to consider buying right now? Here are the bull and bear cases for the medical device giant.

Better Buy: Medtronic vs. Johnson & Johnson

Medtronic (NYSE: MDT) and Johnson & Johnson (NYSE: JNJ) are perfect examples of this type of winning long-term investment. Medtronic sells devices worldwide related to diabetes, cardiovascular, neuroscience, and surgery. Thanks to its vast portfolio, Medtronic has increased earnings over time.

What's in the Cards for Medtronic (MDT) in Q4 Earnings?

Medtronic (MDT) is likely to have prioritized its R&D investments, which might get reflected in the fiscal Q4 results.

• 
  C3.ai (AI) Q4 Loss Narrower Than Expected, Revenues Rise Y/Y

  Zacks
• 
  Avnet (AVT) Up 2.3% Since Last Earnings Report: Can It Continue?

  Zacks

2 Healthcare Stocks You Can Buy and Hold for the Next Decade

Investors who focus on long-term opportunities in the stock market look for well-established companies that are already profitable and have a track record of revenue growth. Two wildly different healthcare companies that both fit that description are Vertex Pharmaceuticals (NASDAQ: VRTX) and Medtronic (NYSE: MDT). Vertex, a biopharmaceutical company founded in 1989, has improved annual revenue by 636% over the past decade.

Medtronic's (MDT) Global Market Share Strong, FX Headwind Stays

Within cardiac rhythm management, Medtronic's (MDT) pacing business continues to outperform the market, banking on strong global growth of its Micra leadless pacemaker family.

Medtronic (MDT) Reports Next Week: Wall Street Expects Earnings Growth

Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

• 
  Will Lennar (LEN) Beat Estimates Again in Its Next Earnings Report?

  Zacks
• 
  Want Better Returns? Don't Ignore These 2 Construction Stocks Set to Beat Earnings

  Zacks